In conclusion, this NMA demonstrated that for NS-NSCLC with PD-L1 ≥ 50%, pembrolizumab plus chemotherapy, tislelizumab plus chemotherapy and sintilimab plus chemotherapy appear to be good treatment options. This evidence concerns the gene CD274 and non-small cell lung carcinoma.